AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04391985
Drug: SOF plus (OBV/PTV/r) plus RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: They were given SOF in a dose of 400 mg/day, and a fixed dose combination of OBV (25 mg), PTV (150 mg), and r (100 mg) taken with food once daily. RBV was supplied in 200 mg capsules, and the recommended dose was 600 mg/ day to reach 1200 mg/day based on patient's body weight and tolerability.
Trial: NCT04375735
Drug: Bovine Lipid Extract Surfactant
RxNorm normalized name: bovine lipid extract surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLES will be administered in doses of 50mg/kg ideal bodyweight, at a concentration of 27mg/ml so a total volume of approximately 2ml/kg will be administered. The material will be instilled via the suction catheter through the ET tube so that the ventilation circuit is not broken. Half of the material will be instilled with the patient positioned on their left and right sides, with a pause to allow 5 min of MV between. The procedure will be repeated at, 24 and 48 hours while intubated, so the patient will receive up to 3 doses. To minimize aerosol generation, all patients will be paralyzed during surfactant administration and the ventilator will be paused. The proposed administration technique, surfactant concentration, volume and dosing schedule is based on previous studies, and has shown to be safe in patients with ARDS.
Trial: NCT01947062
Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 \& 2. The dose of etoposide will be 100mg/m2 on days 1, 2 \& 3.
Trial: NCT03981614
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01783860
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01783860
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00572468
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg of simvastatin
Trial: NCT02723786
Drug: 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
Trial: NCT00603642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered, once a week, for 12 weeks
Trial: NCT01102972
Drug: Reyataz + Norvir + Truvada
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
Trial: NCT04560244
Drug: SHR1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-L1 / TGF-β RII double antibody
Trial: NCT00559182
Drug: Comparator: MK-8033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed.
Trial: NCT01296269
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
Trial: NCT01906879
Drug: triple, quadruple, non-bismuth quadruple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy, quadruple therapy, non-bismuth quadruple therapy
Trial: NCT01227824
Drug: GSK1349572 (dolutegravir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 50 mg taken once daily with or without food
Trial: NCT04503733
Drug: Q4W GMA301 IV injections (300 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Trial: NCT04503733
Drug: Q4W GMA301 IV injections (600 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Trial: NCT04503733
Drug: Q4W GMA301 IV injections (1000 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Trial: NCT04503733
Drug: Q4W GMA301 IV injections (1800 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will contain 12 subjects, 9 of whom will be administered active GMA301 and 3 of whom will be administrated placebo.
Trial: NCT04457531
Drug: LiuWeiLuoBi Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LiuWeiLuoBi Granule is a Chinese medicine made from 6 herbal medicine, including Shaji(Sea-buckthorn), Honghua (Safflower), Jinyinhua(Honeysuckle),etc.
Trial: NCT00792818
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,200 mg/days (oral) divided into 3 times for 28 days
Trial: NCT02494583
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
Trial: NCT04441762
Drug: Intravenous Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac single dose
Trial: NCT04441762
Drug: Intranasal Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac single dose
Trial: NCT02119676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg matching placebo tablets to be administered by mouth
Trial: NCT00288743
Drug: to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02104388
Drug: SJP-0035 Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01935882
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00118456
Drug: AEE788
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01465685
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical to MDMA or methylphenidate
Trial: NCT03344523
Drug: Iron protein succinylate oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron protein succinylate oral solution
Trial: NCT03757390
Drug: Exforge® tab 5/160mg, Crestor® tab 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
Trial: NCT03757390
Drug: CJ-30060 5/160/10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
Trial: NCT01031836
Drug: MEDI-545
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses.
Trial: NCT01031836
Drug: MEDI-545
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses
Trial: NCT01031836
Drug: MEDI-545
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses.
Trial: NCT01031836
Drug: MEDI-545
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses.
Trial: NCT01031836
Drug: MEDI-545
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses
Trial: NCT01031836
Drug: MEDI-545 600
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses.
Trial: NCT03973528
Drug: traditional Chinese medicine: tonifying kidney Wan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional Chinese medicine : tonifying kidney Wan
Trial: NCT02617446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV of matching saline solution
Trial: NCT01330017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
Trial: NCT00216424
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00362180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injections
Trial: NCT03785652
Drug: LY03005 extended-release tablets 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
Trial: NCT03785652
Drug: LY03005 extended-release tablets 120 mg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast
Trial: NCT03785652
Drug: LY03005 extended-release tablets 160 mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast
Trial: NCT03785652
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast
Trial: NCT02032823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
Trial: NCT03914625
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03914625
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03914625
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT01666067
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01666067
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03914625
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03914625
Drug: Mercaptopurine Oral Suspension
RxNorm normalized name: mercaptopurine Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00796887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily
Trial: NCT03914625
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or IV
Trial: NCT03914625
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or IV
Trial: NCT02276027
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 was dosed as 350 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take BYL719 exactly as prescribed.
Trial: NCT04066192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A medically inert placebo medication will be used as described in the study arms.
Trial: NCT02276027
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INC280 was dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to takeINC280 exactly as prescribed.
Trial: NCT02276027
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDK378 was dosed as 750 mg once daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take LDK378 exactly as prescribed.
Trial: NCT02276027
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEK162 was dosed as 45 mg twice daily. On the first day of each cycle, patient received a prescription of adequate drug supply for self-administration at home. The investigator must emphasized compliance and instructed the patient to take MEK162 exactly as prescribed.
Trial: NCT04288323
Drug: Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid
RxNorm normalized name: DIETHYLENETRIAMINE PENTAACETIC ACID
DrugBank: Pentetic acid (DB14007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study involves an on-label use of Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid for the ....
Trial: NCT02099071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01220128
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
Trial: NCT03745820
Drug: BIIB104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00348933
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
Trial: NCT00716833
Drug: Etoricoxibe
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
Trial: NCT00716833
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
Trial: NCT02984072
Drug: Aqueous Cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01220128
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
Trial: NCT01220128
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Trial: NCT01220128
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Trial: NCT01211431
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathécale morphine is used for post-cesarean pain control
Trial: NCT01211431
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
Trial: NCT00338897
Drug: SR123781A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00227734
Drug: capecitabine and oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine and oxaliplatin without cetuximab
Trial: NCT00649311
Drug: eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
Trial: NCT00740805
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00740805
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02508649
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02981628
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02981628
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT02981628
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT03751124
Drug: Estradiol/norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
Trial: NCT03751124
Drug: Placebo for E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
Trial: NCT00408135
Drug: telithromycin (HMR3647)
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01246908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice per day for six weeks.
Trial: NCT01185301
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: weekly oral capsule dosing
Trial: NCT03876301
Drug: Standard of Care FVIII Replacement therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT, THYROID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Trial: NCT00401362
Drug: SC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00924781
Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.